We're running an experiment on ourselves, and we won't know the results until it's too late.
FDA documented over 66,000 adverse reports related to semaglutida through March 2026, with serious complications including gastroparesis, vision loss, and bone density reduction. Unregulated internet purchases of Ozempic lack quality controls, containing impurities and endotoxins that amplify health risks for cosmetic users seeking rapid weight loss.
- FDA documented over 66,000 adverse reports related to semaglutida through March 2026
- Nearly 23,000 reports filed during 2025 alone
- Complications include gastroparesis, intestinal obstruction, muscle loss, and potential irreversible vision loss
- Unregulated internet purchases contain impurities and endotoxins
Ozempic, originally for diabetes treatment, faces safety concerns as off-label cosmetic use surges without medical supervision, with FDA reporting 66,000+ adverse events including vision loss and muscle deterioration.
Ozempic arrived as a breakthrough. The drug, built on a compound called semaglutida, was engineered to help people with type 2 diabetes manage their blood sugar and shed weight. It worked. But somewhere between the pharmacy and the mirror, the story changed. What began as a treatment for a metabolic disease became a shortcut to thinness—pursued by people who had no diabetes at all, buying the medication online without a doctor's permission, chasing the promise of rapid weight loss.
The numbers tell what happened next. By March of this year, the U.S. Food and Drug Administration had logged more than 66,000 adverse event reports tied to semaglutida. In 2025 alone, nearly 23,000 of those reports came in. These were not the mild nausea that early users had warned about. The complications ran deeper: gastroparesis, a condition where the stomach empties too slowly; intestinal blockages; significant loss of muscle mass; weakening of bone density. Regulators in multiple countries began investigating whether the drug was linked to a form of vision loss—ischemic optic neuropathy—that could be permanent.
The problem intensified when the medication moved underground. People buying semaglutida through internet channels, no prescription required, were not getting what they thought they were getting. Recent investigations found that these unregulated products often contained impurities and endotoxins—bacterial contaminants that amplified the risks for anyone injecting them. The pursuit of a thinner body was becoming a gamble with unknown odds.
Yet the full picture is more complicated than a simple cautionary tale. For patients with genuine type 2 diabetes or severe obesity, semaglutida has proven its worth. The research shows real metabolic benefits, real improvements in quality of life. The problem is not the drug itself but the chasm between those who need it and those who want it. Cost remains a barrier for many patients who could legitimately benefit from medical supervision. Meanwhile, people with no medical need are obtaining it through channels no one is monitoring.
What remains unknown is perhaps the most unsettling part. Most clinical trials of semaglutida involved people with diabetes or significant obesity. There is almost no long-term data on what happens when healthy people inject themselves with this compound year after year, chasing aesthetic goals. The gaps in our knowledge are substantial. We do not know what happens to bone density over a decade. We do not know the cumulative effect on vision. We do not know whether the muscle loss reverses or becomes permanent.
The challenge now is to separate the legitimate use from the reckless one. That requires doctors to prescribe carefully, regulators to enforce standards, and people to understand that a medication's effectiveness in one context does not make it safe in another. Until that happens, thousands of people will continue to experience complications that might have been prevented—vision loss that cannot be restored, muscle wasting that takes years to recover, gastrointestinal damage that persists long after the injections stop.
Citas Notables
The principal challenge now is to promote responsible, evidence-based use of the medication— Felipe Díaz-Toro, researcher at the Health Care Research Institute
La Conversación del Hearth Otra perspectiva de la historia
Why did this drug become so popular for cosmetic use when it was never designed for that?
Because it works fast, and the results are visible. In a culture obsessed with quick fixes, a medication that produces measurable weight loss in weeks is irresistible—especially when you can buy it without talking to a doctor.
But people must know it's risky to use a diabetes drug without diabetes.
They know intellectually. But the promise of rapid transformation overrides caution. And there's a gap: the drug is expensive and hard to get legally, but easy to find online. That gap is where the danger lives.
What's the worst that can happen?
Irreversible vision loss. Permanent muscle wasting. Gastrointestinal damage that doesn't heal. These aren't theoretical risks—they're already happening to thousands of people.
Why isn't the FDA stopping this?
The FDA can document what's happening, but they can't control what people buy on the internet from unregulated sellers. The medication itself is legitimate; the distribution channel is the problem.
So the real issue is that we don't actually know what this drug does to healthy people over time?
Exactly. We have data on diabetic patients over several years. We have almost nothing on healthy people using it for aesthetics over a decade. We're running an experiment on ourselves, and we won't know the results until it's too late.